Peripheral Neuropathy Related to Chemotherapy

Seminars in Oncology Nursing

Volumn 23, Issue 3, 2007, Pages 162-173

  Wilkes, Gail ^a  

^a NONE

Author keywords

evidence based practice; motor; Peripheral neuropathy; sensory

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; HUMAN; NURSING; PERIPHERAL NEUROPATHY;

ANTINEOPLASTIC AGENTS; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 34547692762     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2007.05.001     Document Type: Article

References (76)

1. Visovsky C., and Daly B.J. Clinical evaluation and patterns of chemotherapy-induced peripheral neuropathy. J Am Acad Nurse Pract 16 (2004) 353-359
2. Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Invest 21 (2003) 439-451
3. Postma T.J., Heimans J.J., Muller M.J., et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9 (1998) 739-744
4. Dunlap B., and Paice J.A. Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol 4 (2006) 398-399
5. Wul FL, Brites C, Quevedo S, et al. Difference in the evaluation of symptoms between patients and their doctors in an oncologic hospital [abstr 2874] Proc Am Soc Clin Oncol 2002;21:264b.
6. Varricchio C.G., Bass E., Novotny P., et al. Common toxicity criteria versus symptom specific measures: how congruent are the data [abstr 2897]?. Proc Am Soc Clin Oncol 21 (2002) 270b
7. Stephens R.J., Hopwood P., Girling D.J., et al. Randomized trials with quality of life end points: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?. Qual Life Res 6 (1997) 225-236
8. Ostchega Y., Donohue M., and Fox N. High-dose cisplatin-related peripheral neuropathy. Cancer Nurs 11 (1988) 23-32
9. Hay J.W. Quality of life effects of chemotherapy-induced neuropathy in ovarian cancer. [abstr 886]. Proc Am Soc Clin Oncol 21 (2002) 222a
10. Hausheer F.H., Schilsky R.L., Bain S., et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33 (2006) 15-49
11. Postma T., and Heimans J. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11 (2000) 509-513
12. Armstrong T., Almadrones L., and Gilbert M.R. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 32 (2005) 305-311
13. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 249 (2002) 9-17
14. Corse A.M., and Kunel R.W. Peripheral neuropathy. In: Barker L.R., Burton J.R., and Zieve P.D. (Eds). Principles of ambulatory medicine. Ed 5 (1999), Williams and Wilkins, Baltimore, MD 1296-1314
15. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5 suppl 1 (2005) S38-S46
16. Kuncl R.W., and George E.B. Toxic neuropathies and myopathies. Curr Opin Neurol 6 (1993) 695-704
17. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chemo-modulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
18. Eloxatin [package insert] (2006), sanofi-aventis US, LLC, Bridgewater, NJ August.
19. Abraxane [package insert] (2005), Abraxis Oncology, Schaumberg, IL January.
20. Johnson S.A., Harper P., Hortobagyi G.N., et al. Vinorelbine: an overview. Cancer Treat Rev 22 (1996) 127-142
21. Richardson P.G., Briemberg H., Jagannath S., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24 (2006) 3113-3120
22. Mileshkin L., Stark R., Day B., et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24 (2006) 4507-4514
23. Mielke S., Mross K., Gerds T.A., et al. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 14 (2003) 785-792
24. de Gramont A., Boni C., Navaro M., et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a medican follow-up of 4 years. [abstr 3501]. J Clin Oncol 23 suppl (2005) 16S
25. Lehky T.J., Leonard G.D., Wilson R.H., et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29 (2004) 387-392
26. Davis I.D., Kiers L., MacGregor L., et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 11 (2005) 1890-1898
27. Bianchi G., Vitali G., Caraceni A., et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41 (2005) 1746-1750
28. Maestri A., DePasqualae Ceratti A., Cundari S., et al. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin- induced peripheral neuropathy. Tumori 91 (2005) 135-138
29. Gedlicka C., Sheithauer W., Schull B., et al. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. [letter]. J Clin Oncol 20 (2002) 3359-3361
30. Hilpert F., Stahle A., Tome O., et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy: a double-blind, placebo controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) ovarian cancer study group. Support Care Cancer 13 (2005) 797-805
31. Lorusso D., Ferrandine G., Greggi S., et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 14 (2003) 1086-1093
32. Openshaw H., Beamon K., Synold T.W., et al. Neurophysiological study of peripheral neuropathy after high dose paclitaxel. Clin Cancer Res 10 (2004) 461-467
33. Moore D.H., Donnelly J., McGuire W.P., et al. Limited access trial using amifostine for protection against cisplatin- and three hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 21 (2003) 4207-4213
34. Sevelda P., Sevelda U., Denison U., et al. Cytoprotection of amifostine (A) in ovarian cancer patients receiving paclitaxel/carboplatin (PC) first line chemotherapy in a multi-center phase III trial. [abstr 5021]. J Clin Oncol 22 suppl4 (2004) 254s
35. Leong S.S., Tan E.H., Fong K.W., et al. Randomized, double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small cell lung cancer. J Clin Oncol 21 (2003) 1767-1774
36. Gelmon K., Eisenhauer E., Bryce C., et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17 (1999) 3038-3047
37. Socinski M.A., Tynan M., Natoli S., et al. Phase III trial of paclitaxel (P), carboplatin (C) and amifostine in stage IV non-small cell lung cancer (NSCLC). [abstr 2015]. Proc Am Soc Clin Oncol 1 (1999) 303
38. Gradishar W.J., Stephenson P., Glover D.J., et al. A phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188). Cancer 92 (2001) 2517-2522
39. Penz M., Kornek G.V., Raderer M., et al. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. [letter]. Ann Oncol 12 (2001) 421-422
40. Takeda K., Negoro S., Matsui K., et al. Phase I safety and pharmacokinetic trial of BNP7787 in patients receiving cisplatin (CDDP) and paclitaxel (PTX) for advanced non-small cell lung cancer (NSCLC). An Osaka phase I study group trial. [abstr 453]. Proc Am Soc Clin Oncol 19 (2002) 114a
41. Gamelin L., Boisdron-Celle M., Delva R., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10 (2004) 4055-4061
42. Saif M.W. Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Appl Res 4 (2004) 576-582
43. Wilson R.H., Lehky T., Thomas R.R., et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20 (2002) 1767-1774
44. Eckel F., Schmelz R., Erdmann J., et al. Prevention of oxaliplatin induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. [abstr 579]. Proc Am Soc Clin Oncol 20 (2001) 146
45. Lersch C., Schmelz R., Eckel F., et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2 (2002) 54-58
46. Mariani G., Garrone O., Granetto C., et al. Oxaliplatin induced neuropathy: could gabapentin be the answer?. [abstr 2397]. Proc Am Soc Clin Oncol 19 (2000) 609a
47. Wong G.Y., Michalak J.C., Sloan J.A., et al. A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: a North Central Cancer Treatment Group Study. [abstr]. J Clin Oncol 23 suppl 16S (2005) 8001
48. Marshall J., Zakari A., Hwang J., et al. Ginkgo biloba (GB) extract as a neuroprotective agent in oxaliplatin (Ox)-induced neuropathy. American Society of Clinical Oncologists Annual Meeting Proceedings. [abstr 3670]. J Clin Oncol 22 suppl 14S (2004) 3670
49. Vahdat L., Papdopoulos K., Lange D., et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Cancer Clin Res 7 (2001) 1192-1197
50. Cascinu S., Catalano V., Cordella L., et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo controlled trial. J Clin Oncol 20 (2002) 3478-3483
51. Renno S.I., Rao R.D., Sloan J., et al. The efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase III randomized, double blind, placebo-controlled NCCTG trial, N01C3. [abstr A-8530]. J Clin Oncol 24 suppl 18 (2006) 475s
52. Roberts J.A., Jenison E.L., Kim K., et al. A randomized, double-blind placebo controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 67 (1997) 172-177
53. Koeppen S., Verstappen C.C.P., Korte R., et al. Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. Cancer Res Clin Oncol 130 (2004) 153-160
54. Durand J.P., Brezault C., and Goldwasser F. Protection against oxaliplatin acute sensory toxicity by venlafaxine. Anticancer Drugs 14 (2003) 423-425
55. Argyriou A.A., Chroni E., Koutras A., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurol 64 (2005) 26-31
56. Cassidy J., Bjarnason G.A., Hickish T., et al. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). 2006 American Society of Clinical Oncologists Annual Meeting Proceedings Part I. [abstr]. J Clin Oncol 24 suppl 18S (2006) 3507
57. Lee J.J., and Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24 (2006) 1633-1642
58. Pisano C., Pratesi G., Laccabue D., et al. Paclitaxel and cisplatin-induced neuropathy: a protective role of acetyl-L-carnitine. Clin Cancer Res 9 (2005) 5756-5767
59. Nagamatsu M., Nickander K.K., Schmelzer J.D., et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18 (1995) 1160-1167
60. Schuchter L.M., Hensley M.L., Meropol N.J., et al. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 20 (2002) 2895-2903
61. Armstrong CM, Cota G. Calcium block of Na+ channels and its effect on closing rate Proc Natl Acad Sci U S A 1999;96:4145-4157.
62. Boyle F.M., Wheeler H.R., and Shenfield G.M. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 41 (1999) 107-116
63. Tredici G., Cavaletti G., Petruccioli M.G., et al. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology 15 (1994) 701-704
64. Lecomte T., Landi B., Beaune P., et al. Glutathione S-tranferase P1 polymorphism (IIe105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12 (2006) 3050-3056
65. Guay D.R. Adjunctive agents in the management of chronic pain. Pharmacotherapy 21 (2001) 1070-1081
66. Eisenberg E., Lurie Y., Braker C., et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 57 (2001) 505-509
67. Apfel S.C., Scwartz S., and Bruce T. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. JAMA 284 (2000) 2215-2221
68. van der Hoop R.G., Vecht C.J., van der Burg M.E., et al. An ACTH-(4-9) analog prevents cisplatin-induced neuropathy in ovarian cancer patients. N Engl J Med 332 (1990) 89-94
69. Davis J.L., and Smith R.L. Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules. Diabetes Care 22 (1999) 1909-1910
70. Viscovsky C. Measuring oncology nursing-sensitive patient outcomes: evidence-based summary. Available at: http://onsopcontent.ons.org/toolkits/evidence/Clinical/pdf/NeuropathySum mary.pdf. (accessed November 23, 2006).
71. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-A GERCOR study. J Clin Oncol 24 (2006) 394-400
72. Seidman A.D., Berry D., Cirrincione C., et al. CALGB 9840: phase III study of weekly paclitaxel via 1-hour (h) infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2 normal MBC. [abstr 512]. Proc Am Soc Clin Oncol 22 (2004) 6s
73. Gelderblom H., Mross K., ten Tije A.J., et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20 (2002) 574-581
74. Mielke S., Sparreboom A., and Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimens. Eur J Cancer 42 (2006) 24-30
75. Seidman A.D., Hudis C.A., Albanel J., et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16 (1998) 3353-3361
76. Wong R., and Sagar S. Acupuncture treatment for chemotherapy-induced peripheral neuropathy. Acupunct Med 24 (2006) 87-91